Theralase Technologies Inc.
TLT.V
Toronto Stock Exchange Ventures0.27
CAD
+0.01
- -
Theralase Technologies Inc.
TLT.V
(Toronto Stock Exchange Ventures)
Recent
price
0.27
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Theralase Technologies Inc. operates as a clinical-stage pharmaceutical firm, dedicated to the investigation and advancement of sophisticated Photo Dynamic Compounds (PDCs) and their specialized drug formulations across Canada, the United States, and international markets. This innovative approach targets the elimination of various cancers, bacteria, and viruses. Concurrently, the company designs, develops, manufactures, and distributes its patented super-pulsed laser technology, specifically cleared for treating chronic knee discomfort and utilized off-label for ameliorating a spectrum of nerve, muscle, and joint conditions. A primary focus for Theralase is TLD-1433, known as Ruvidar™, which is currently undergoing a pivotal Phase II clinical study for the treatment of Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ. Enrollment for this study is nearing completion, with the company aiming for New Drug Application submissions to Health Canada and the FDA by the fourth quarter of 2026, potentially leading to regulatory approval in early 2027. Recent preclinical findings have also demonstrated the efficacy of Ruvidar® against Herpes Simplex Virus Type 1 and the potential for an X-ray activated version, Rutherrin®, in various cancer models. Beyond its drug development, Theralase markets its Cool Laser Therapy (CLT) systems, which include devices like the TLC-2000, to healthcare professionals. These systems utilize dual-wavelength, super-pulsed laser technology to penetrate tissue deeply, facilitating pain relief, reducing inflammation, and accelerating cellular healing. Founded in 1994, Theralase Technologies Inc. is headquartered in Toronto, Canada, and continues its mission of "Destroying Cancer at the Speed of Light®" and "Healing Pain at the Speed of Light®."
Theralase(R) Lists Warrants on the TSXV
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study